Infusion Providers Alliance
Association representing infusion drug providers.
Based in DE
🤖
AI Overview
With $1.5M in lobbying spend across 19 quarterly filings, Infusion Providers Alliance is a significant lobbying presence.
$1.5M
Total Lobbying Spend
19
Quarterly Filings
1
Lobbying Firms Used
4
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2020 | $120K |
| 2021 | $160K |
| 2022 | $320K |
| 2023 | $320K |
| 2024 | $240K |
| 2025 | $360K |
Lobbying Firms
THE MCMANUS GROUP
What They Lobby For
- Issues related to Medicare Part B.
- Access to Part B drugs.
- Access to Part B drugs. Most Favored Nation (MFN) Model, (CMS-5528-IFC). Extension of Medicare sequester delay in Division N Sec. 102 of H.R. 133 The Consolidated Appropriations Act of 2020.
- Access and appropriate reimbursement to Part B drugs. Extension to Medicare sequester delay in S. 748 - A Bill to Provide for an Extension of the Temporary Suspension of Medicare Sequestration During the COVID-19 Public Health Emergency, H.R. 1868 - To Prevent Across-The-Board Direct Spending Cuts, and For Other Purposes, H.R. 315 - Medicare Sequester COVID Moratorium Act and H.R.1999 - To delay and offset the sequester under the Statutory Pay-As-You-Go Act of 2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes.
- Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act. Support of reinstating step therapy prohibition in Medicare Advantage Plans for Part B drugs. Issues related to provider payment cuts addressed in S. 610 - Protecting Medicare and American Farmers from Sequester Cuts Act and H.R. 6143 - Supporting Health Care Providers During the COVID-19 Pandemic Act.
- Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies. Access to Alzheimer's Disease therapies.
- Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies.
- Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
- Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies. Issues related to physician payments included in H.R.8800 - Supporting Medicare Providers Act of 2022.
- Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies. Issues related to payments cuts to the Medicare Physician Fee Schedule including in H.R.8800 - Supporting Medicare Providers Act of 2022 and Sec. 4112 of H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328)/
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.